Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have prostate cancer that has spread to other parts of the body (metastatic) and is no longer responding to hormone therapy
- You have tried at least one newer hormone therapy (like enzalutamide or abiraterone) and it stopped working or caused bad side effects
- You have not had more than 2 types of chemotherapy for your cancer
- You are able to provide a tumor tissue sample (from a previous biopsy or a new one) for testing
- You are in generally good health aside from the cancer, with an ECOG score of 0 or 1 (meaning you can do most daily activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new injectable treatment called 3D1015 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to target cancer cells using a special imaging marker that shows up on PET scans.
This trial tests a new investigational medicine (TY-302) combined with abiraterone, a standard hormone-blocking drug, in men with metastatic castration-resistant prostate cancer. It aims to see if this combination can slow cancer growth after initial hormone therapy stops working.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This trial tests a new drug called QLS2401 for patients with advanced prostate cancer that has spread and no longer responds to standard treatments. The goal is to see if it can help control the cancer.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.